FDA 2026 NAMs Guidance on Human-Relevant Evidence

added blog Health

2026-05-06 04:11:46 -

The FDA’s March 2026 draft guidance on new approach methodologies (NAMs) is more than a policy statement; it is a signal that evidence from non-animal testing is moving closer to mainstream Regulatory decision-making. While the draft does not impose a blanket acceptance rule for sponsors, it clearly articulates a scientific framework that explains when and how NAMs can inform drug...

0 Comments 0 Shares 59 Views 0 Reviews